

REVIEW ARTICLE

Implications of the changing epidemiology of inflammatory bowel disease in a changing world

Manasi Agrawal^{1,2}  | Tine Jess^{1,3}¹Department of Clinical Medicine, Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Aalborg University, Copenhagen, Denmark²The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA³Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark**Correspondence**

Manasi Agrawal, The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Email: manasi.agrawal@mountsinai.org

Funding information

Danmarks Grundforskningsfond, Grant/Award Number: DNRF148; National Institute of Diabetes and Digestive and Kidney Diseases, Grant/Award Number: K23DK129762-02

Abstract

The epidemiology of inflammatory bowel disease (IBD) has undergone considerable shifts since its emergence in the Western world over a century ago, especially in the last few decades, with increasing global burden of disease. IBD incidence continues to rise in developed countries in all age groups which is contributing to compounding prevalence. Further, IBD incidence is rising sharply in Asia and other recently developed and developing countries. In this review, we discuss the implications of changing trends of IBD epidemiology. First, changing patterns provide insights into IBD causes, as they occur concurrent with shifts in the environment, cultures, and attitudes. Understanding the impact of the environment on IBD risk can help towards prediction and prevention strategies. Second, we must prepare healthcare systems for the rising burden of IBD and address it at various levels towards improving outcomes and health, overall.

KEYWORDS

Crohn's disease, epidemiology, inflammatory bowel disease, prevention, ulcerative colitis

INTRODUCTION

The epidemiology of inflammatory bowel disease (IBD) has undergone considerable shifts since its emergence in the Western world over a century ago.^{1,2} IBD incidence is sharply increasing in developing and recently developed countries. IBD incidence continues to rise in developed countries among children and older age groups, which is contributing to compounding prevalence.³⁻⁵ Previously believed to be a disease of children and young adults, IBD is increasingly being reported in older individuals and the elderly.⁵ Further, IBD incidence is rising at an alarming rate in recently developed and developing countries.²

In this review, we discuss the implications of changing trends of IBD epidemiology. First, these patterns provide insights into IBD causes as they occur concurrent with shifts in the environment, cultures, and attitudes. Second, we must prepare for the rising burden of IBD and address it at various levels, guided by the principles of disease prevention.

UNDERSTANDING NONGENETIC IBD RISK FACTORS

IBD causality has been a subject of immense research over the last decades paving the way for insights into IBD pathogenesis. Genome

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.

wide association study have identified important polymorphisms towards IBD risk.⁶ However, there is marked heterogeneity in risk variants across populations and limited concordance within families, including between monozygotic twins.^{7,8} The rise of IBD has been in parallel with industrialization and major shifts in the environment.^{2,9} Immigration from a developing country to a western country is associated with an increase in the risk of IBD and other immune mediated diseases.^{10,11} These indirect data corroborate the role of nongenetic factors towards IBD. Here, we categorize them into factors pertaining to the environment, lifestyle, and health (Figure 1).

The environment

Traditional epidemiological studies leveraging questionnaire and register data have been informative in understanding individual-level risk factors, but a study of more ubiquitous environmental exposures has become possible only recently, when advanced and innovative analytical techniques came to the forefront. Geographic information system leverages geographic data, obtained via satellites, to quantify environmental variables such as specific pollutants, greenspace, and biodiversity. These variables, transformed into indices, can be measured by location and time, leading to a quantification of the dose and duration of these exposures and modeling of outcomes as a function of these factors.

Leveraging GIS data, in a population-based study from Ontario, early life exposure to pollution (reactive oxygen species) was associated with later risk of IBD.¹² Residential green space during the early life period was found to be protective against IBD in a dose-dependent manner.¹³ These data are consistent with other reports on the protective effect of greenspace on health and mortality.¹⁴⁻¹⁶ Relatedly, blue space, a measure of water bodies, was protective against IBD in an analysis of the UK Biobank data.¹⁷ The mechanisms through which environmental health may be causally related to human health are not well-elucidated, but improved immune tolerance, lower stress levels, improved diet and physical activity and lower

exposure to pollutants may be some potential mechanisms. Certainly, various chemicals, ubiquitous in the urban world, are linked with downstream risk of adverse health outcomes.¹⁸ For example, per- and polyfluoroalkyl substances (PFAS) are endocrine disruptive chemical ubiquitous and long-lasting in the environment implicated in many diseases.¹⁹ PFAS may also have a role in IBD, although data are conflicting.^{20,21} Heavy metals are also important health mediators of disease. In a pilot study, on mass spectrometric analysis of deciduous teeth, prenatal lead exposure was associated with future risk of IBD.²²

Lifestyle

Urbanization and cultural shifts have led to vast changes in diet, habits, activity, and stress. Chronic disease states, including IBD, parallel these shifts. Here, we discuss the lifestyle factors that are most consistently linked with IBD.

Breastfeeding influences offspring immune modulation, microbiome establishment, and risk of many chronic diseases later in life. In a systematic review of 35 epidemiological studies, being breastfed was associated with a protective effect against CD and UC (OR 0.71, 95% CI 0.59, 0.85 and 0.78, 0.67, 0.91, respectively) in a dose dependent manner, and across populations.²³ Mechanistic data further corroborate this association; for example, human milk oligosaccharides, modulate offspring gut microbiome and mucosal immune maturation.²⁴ In addition, formula feeds, the typical alternative to breastfeeding, contain emulsifiers and other synthetic molecules, which are implicated in intestinal inflammation and host-microbe interactions.^{25,26}

Recent data have substantiated the role of modern and urban diets in IBD. In a prospective cohort from 21 countries including 116,087 individuals, consumption of ultra-processed foods was associated with incident IBD in a dose dependent manner (HR 1.82, 95% CI 1.22, 2.72 for ≥ 5 servings/day compared to <1 serving/day, $p_{\text{trend}} = 0.006$).²⁷ Data from the Nurses' Health Study corroborated




FIGURE 1 Environmental, lifestyle and health-related risk factors implicated in IBD risk. IBD, inflammatory bowel disease

these findings.²⁸ Mechanistic data add further support; synthetic emulsifiers, such as carboxymethylcellulose and polysorbate-80, are implicated in disrupting the intestinal mucosal barrier in mice as well as in humans in a pilot clinical trial.^{25,29} Food coloring agents, for example, Red 40 and Yellow 6, have been linked with intestinal inflammation in mice models with augmented IL-23 expression.²⁶ Conversely, Mediterranean diet, which is rich in naturally-sourced and wholesome foods such as vegetables, fruits, fish and nuts, was protective against CD in a Swedish cohort ($p_{\text{trend}} = 0.03$).³⁰ Dietary factors have significant downstream metabolic implications.³¹

Next, smoking is associated with CD risk, disease progression, and reduced response to biologics.^{32,33} In the context of UC, the data are less clear. Prenatal exposure to smoke has been linked with offspring IBD risk in multiple studies.^{34–36} Smoking later in childhood also increases the risk of both CD and UC.³⁶ The effect of smoking on IBD risk is likely to be mediated through epigenetic alterations, at least in part. Certainly, there are indirect lines of evidence to support this. Smoking is a strong risk factor for downstream DNA methylation changes.^{37,38} These are, in turn, implicated in IBD risk.^{39,40}

Other lifestyle factors such as stress, anxiety, and lack of physical activity, which are ingrained in the modern and urban society, are also implicated in IBD risk. In a Nurses' Health Cohort of over 3 million person years follow up physical activity was associated with a protective effect against CD ($p_{\text{trend}} = 0.02$).⁴¹ Whether these risk factors may themselves be causal, or a surrogate for other exposures, is yet to be teased out.

Health-related

Infections have been implicated in IBD risk across studies.^{42,43} In particular, gastrointestinal bacterial infections such as *Salmonella* and *Campylobacter* species have been associated with IBD; however detection bias is likely to play a role in this association.^{44,45} Conversely, *Helicobacter pylori* may have a protective role against IBD. In a Taiwanese study, *H. pylori* eradication, after adjusting for antibiotic use, was associated with increased risk of immune mediated diseases, including IBD.⁴⁶ This may be potentially mediated by a direct tolerogenic effect, or an indirect effect via regulation of the gut microbiome and mucosal homeostasis.^{47,48} These data emphasize “the hygiene hypothesis” which refers to altered immune tolerance with improving hygiene.⁴⁹

Antibiotic use across all age groups has been linked with an increased risk of IBD in a dose-dependent manner. In a population-based cohort study, we reported that ≥ 3 , but not fewer, courses of antibiotics during pregnancy increased UC risk in the offspring by 45% (aHR 1.45, 95% CI 1.06, 2.00).⁵⁰ Consistent findings were reported in a nested case-control study of an Italian birth cohort.⁵¹ Increasing number of antibiotics courses also increase IBD risk among those ≥ 60 years of age.⁵² Broad-spectrum antibiotics may lead to greater risk compared to narrow-spectrum antibiotics.⁵³ These data implicate antibiotic-mediated gut microbiome disruption in IBD pathogenesis.⁵⁴ In a recent population-based study, early life

exposure to mebendazole, a broad spectrum anthelmintic agent, was associated with a 32% increased risk of adult-onset UC (aHR 1.33, 95% CI 1.13, 1.56), but not CD.⁵⁵

Appendicitis and appendectomy have been implicated in IBD risk. In a Swedish cohort study, appendectomy at age < 20 years for appendicitis or mesenteric lymphadenitis was associated with a lower risk of UC.⁵⁶ Similar results were reported upon combining data from Swedish and Danish registers.⁵⁷ Interestingly, in a Danish cohort study of familial units, individuals with first-degree relatives with appendicitis, but not own history of appendicitis, at age < 20 years had a lower risk of UC. This risk was even lower in those with family history of UC.⁵⁸ These data bring into question the role of appendicitis, including shared risk factors for appendicitis, rather than appendectomy, in modulating IBD risk. Further, appendicitis and appendectomy are also reported to modulate UC course.⁵⁹

Timing of exposure: The early life period versus later in life

Additional important considerations are the timing of exposure as well as the timing of disease onset. The early life period, which extends from the prenatal period to early childhood, is a critical window for immune development and microbiome establishment, and exposures during this period confer a long-lasting effect on the offspring.^{60,61} This hypothesis, known as the Developmental Origins of Health and Disease, is relevant to IBD. Many of the exposures described above are operative during the early life period.^{42,50} Conversely, older onset IBD may have different underlying mechanisms, for example, age related immune senescence.⁶²

RESPONSE TO THE RISING IBD BURDEN

IBD is a life course disease, often occurs in children and young adults, and it has no cure. It is associated with complications such as infections, hospitalizations, surgeries, and cancer.^{63,64} IBD leads to adverse impact on mental health and on disability.^{65,66} The management of IBD involves long-term use of biologics and small molecules, and complex surgeries, each of which incurs substantial healthcare costs. The direct healthcare costs attributed to an IBD patient are estimated to be three times those attributed to a non-IBD patient, and with increasing trends over the years.⁶⁷ Further, IBD is associated with indirect societal costs which can be more occult and pervasive.⁶⁸

As the incidence and prevalence of IBD continue to rise, including and especially in developing countries, the urgency to prepare healthcare systems and mitigate its impact cannot be overstated. Strategies towards IBD prediction and prevention are important in the larger public health and economic context. Here, we can apply the principles of disease prevention, analogous to what is done in other chronic diseases such as diabetes and cardiovascular disease, to manage the impact of IBD.⁶⁹ Such preventive strategies




FIGURE 2 Levels of IBD prevention. IBD, inflammatory bowel disease

are also relevant to other immune mediated diseases, which have significant overlap during the preclinical phase.⁷⁰ We lead the discussion with tertiary prevention, a goal that is largely achieved, and move towards primordial prevention, which we aspire to achieve (Figure 2).

Tertiary prevention: Early IBD treatment

Robust data demonstrate that early treatment of IBD is critical to prevent complications. In a meta-analysis of CD clinical trials and real world data, treatment with biologics within 2 years of diagnosis was associated with higher rates of remission and mucosal healing compared to late or non-biologic treatment.⁷¹ Treat-to-target is a key concept in IBD; the STRIDE2 guidelines advocate to strive for clinical, endoscopic and biomarker remission in CD and UC.⁷² In the long-term follow up data from the CALM trial, patients with recently-diagnosed CD who achieved deep remission at 1 year had a lower risk of disease progression compared to patients who did not.⁷³ Like CD, UC is also a progressive disease; while data on long-term outcomes with early therapy are lacking, it is reasonable to institute early and adequate treatment to lower the risk of colectomy and colorectal cancer.⁷⁴ IBD in older individuals warrants additional considerations around frailty, comorbid conditions, and medications interactions.⁷⁵

Secondary prevention: Early IBD diagnosis

Early diagnosis, an indispensable step towards early treatment, is highly relevant in the context of IBD. CD can be associated with varied and nonspecific symptoms, thereby leading to delay in diagnosis. In a Swiss cohort of IBD patients, adults with delay in CD diagnosis were more likely to present with strictures, fistulas and other complications.⁷⁶ Similarly, in data from France, delay in CD diagnosis by 13 months or longer was associated with an increased risk of surgery.⁷⁷ In order to minimize delay in diagnosis, Danese et al developed the Red Flag Index, a questionnaire of relevant signs and symptoms.⁷⁸ This, in combination with fecal calprotectin, has been validated as a tool for early CD diagnosis.⁷⁹

Primary prevention: Decreasing IBD risk among at risk individuals

Primary prevention implies decreasing risk among at risk individuals thereby preventing the onset of disease. Genetic risk for IBD, represented by family history of IBD, particularly among first degree relatives, is considered one of the strongest risk factors for IBD.⁸⁰ Individuals with immune-mediated diseases such as lupus, rheumatoid arthritis and ankylosing spondylitis are at risk for IBD.⁸¹ Parental history of an immune-mediated disease is also a risk factor for IBD.⁸²

Preclinical IBD, a period of immune dysfunction and microbiome perturbations at a subclinical level also represents the “at risk” state.⁸³ The Genetics, Environment, and Microbiome study has demonstrated that increased intestinal permeability among FDRs of individuals with CD is associated with increased risk of CD (HR 3.03, 95% CI, 1.64, 5.63) as long as 3 years prior to CD diagnosis.⁸⁴ In a pilot study of 13 individuals, the group identified a microbiome signature detectable via increased fecal proteolytic and elastase activity predictive of UC onset.⁸⁵ In a proteomic analysis of serum samples from military recruits, the PREDICTS (Proteomic Evaluation and Discovery in an IBD Cohort of Tri-Service Subjects) study identified that signatures pertaining to antimicrobial antigens, complement cascade, innate immunity, and glycosaminoglycan and lysosome metabolism up to 5 years prior to CD onset (areas under the receiver operating characteristic curve: 0.76 and 0.86, 5 years and 1 year before diagnosis, respectively).⁸⁶ Further, anti-granulocyte macrophage-colony stimulating factor antibodies predicted CD diagnosis, as well as complicated disease course.⁸⁷ These and other ongoing works are key to characterize preclinical IBD towards prediction and prevention.

The next step in primary prevention is to identify an intervention to prevent IBD onset in at risk individuals. Key features of such an intervention would be safety, effectiveness, and ease of administration. While these are early data, orally administered phage therapy targeting pathogenic *Klebsiella pneumoniae* strains attenuated inflammation in IBD models and were safe in healthy volunteers.⁸⁸ Further research in this area is eagerly awaited.

Primordial prevention: Decreasing prevalence of risk factors

Finally, the overarching goal would be to apply the principles of prevention to the general population and work towards decreasing the prevalence of risk factors for IBD and other chronic diseases. Towards that goal, we must take steps towards environmental justice, such as restricting fossil fuels use, minimizing pollution, implementing sustainable practice, and fighting climate change. These efforts are needed at individual, societal, country, and global levels. Relatedly, lifestyle changes such as healthful diets, minimizing intake of processed foods, avoiding smoking, and spending time in nature would be considerations, not only in the context of IBD, but also towards improving health overall.

CONCLUSION

In summary, the evolving epidemiology of IBD on a global scale provides important insights into IBD risk and pathogenesis. Environmental health is closely linked to IBD risk and outcomes, as is the case with other chronic diseases. As the burden of IBD changes, we must prepare healthcare systems globally to mitigate its impact

through early diagnosis and early treatment. We are making strides in our vision of IBD prediction and prevention.

AUTHOR CONTRIBUTIONS

Manasi Agrawal: concept, literature search, drafting of manuscript and critical revision of the manuscript for important intellectual content; Tine Jess: concept, drafting of manuscript and critical revision of the manuscript for important intellectual content.

ACKNOWLEDGEMENT

We thank Jill Gregory, Certified Medical Illustrator, Icahn School of Medicine at Mount Sinai, for the illustrations. Danish National Research Foundation, grant no. DNRF148. MA is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK129762-02).

CONFLICT OF INTEREST

The corresponding author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated. MA reports no conflict of interest. TJ reports no conflict of interest.

DATA AVAILABILITY STATEMENT

A data availability statement is not applicable here as this paper includes no original data.

ORCID

Manasi Agrawal  <https://orcid.org/0000-0003-4729-1485>

REFERENCES

1. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol.* 2021;18(1):56–66. <https://doi.org/10.1038/s41575-020-00360-x>
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet.* 2018;390(10114):2769–78. [https://doi.org/10.1016/s0140-6736\(17\)32448-0](https://doi.org/10.1016/s0140-6736(17)32448-0)
3. Kuenzig ME, Fung SG, Marderfeld L, Mak JW, Kaplan GG, Ng SC, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. *Gastroenterology.* 2022;162(4):1147–59.e4. <https://doi.org/10.1053/j.gastro.2021.12.282>
4. Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. *Gastroenterology.* 2019;156(5):1345–53.e4. <https://doi.org/10.1053/j.gastro.2019.01.002>
5. Agrawal M, Christensen HS, Bøgsted M, Colombel JF, Jess T, Allin KH. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. *Gastroenterology.* 2022. <https://doi.org/10.1053/j.gastro.2022.07.062>
6. Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. *Nature.* 2020;578(7796):527–39. <https://doi.org/10.1038/s41586-020-2025-2>

7. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet.* 2015;47(9):979–86. <https://doi.org/10.1038/ng.3359>
8. Jess T, Riis L, Jespersgaard C, Hougs L, Andersen PS, Orholm MK, et al. Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. *Am J Gastroenterol.* 2005;100(11):2486–92. <https://doi.org/10.1111/j.1572-0241.2005.00224.x>
9. Kaplan GG. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol.* 2015;12:720–7. <https://doi.org/10.1038/nrgastro.2015.150>
10. Agrawal M, Corn G, Shrestha S, Nielsen NM, Frisch M, Colombel JF, et al. Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study. *Gut.* 2020;70(6):1037–43. <https://doi.org/10.1136/gutjnl-2020-321798>
11. Agrawal M, Shah S, Patel A, Pinotti R, Colombel JF, Burisch J. Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies. *J Autoimmun.* 2019;105:102303. <https://doi.org/10.1016/j.jaut.2019.07.002>
12. Elten M, Benchimol EI, Fell DB, Kuenzig ME, Smith G, Chen H, et al. Ambient air pollution and the risk of pediatric-onset inflammatory bowel disease: a population-based cohort study. *Environ Int.* 2020;138:105676. <https://doi.org/10.1016/j.envint.2020.105676>
13. Elten M, Benchimol EI, Fell DB, Kuenzig ME, Smith G, Kaplan GG, et al. Residential greenspace in childhood reduces risk of pediatric inflammatory bowel disease: a population-based cohort study. *Am J Gastroenterol.* 2020;116(2):347–53. <https://doi.org/10.14309/ajg.0000000000000990>
14. Twohig-Bennett C, Jones A. The health benefits of the great outdoors: a systematic review and meta-analysis of greenspace exposure and health outcomes. *Environ Res.* 2018;166:628–37. <https://doi.org/10.1016/j.envres.2018.06.030>
15. Ribeiro AI, Tavares C, Guttentag A, Barros H. Association between neighbourhood green space and biological markers in school-aged children. Findings from the Generation XXI birth cohort. *Environ Int.* 2019;132:105070. <https://doi.org/10.1016/j.envint.2019.105070>
16. Bauwelinck M, Casas L, Nawrot TS, Nemery B, Trabelsi S, Thomas I, et al. Residing in urban areas with higher green space is associated with lower mortality risk: a census-based cohort study with ten years of follow-up. *Environ Int.* 2021;148:106365. <https://doi.org/10.1016/j.envint.2020.106365>
17. Zhang Z, Chen L, Qian ZM, Li H, Cai M, Wang X, et al. Residential green and blue space associated with lower risk of adult-onset inflammatory bowel disease: findings from a large prospective cohort study. *Environ Int.* 2022;160:107084. <https://doi.org/10.1016/j.envint.2022.107084>
18. Peters A, Nawrot TS, Baccarelli AA. Hallmarks of environmental insults. *Cell.* 2021;184(6):1455–68. <https://doi.org/10.1016/j.cell.2021.01.043>
19. Jane LEL, Yamada M, Ford J, Owens G, Prow T, Juhasz A. Health-related toxicity of emerging per- and polyfluoroalkyl substances: comparison to legacy PFOS and PFOA. *Environ Res.* 2022;212:113431. <https://doi.org/10.1016/j.envres.2022.113431>
20. Steenland K, Zhao L, Winquist A. A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). *Occup Environ Med.* 2015;72(5):373–80. <https://doi.org/10.1136/oemed-2014-102364>
21. Lochhead P, Khalili H, Ananthakrishnan AN, Burke KE, Richter JM, Sun Q, et al. Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: a nested case control analysis in the Nurses' Health Study cohorts. *Environ Res.* 2021;207:112222. <https://doi.org/10.1016/j.envres.2021.112222>
22. Nair N, Austin C, Curtin P, Gouveia C, Arora M, Torres J, et al. Association between early-life exposures and inflammatory bowel diseases, based on analyses of deciduous teeth. *Gastroenterology.* 2020;159(1):383–5. <https://doi.org/10.1053/j.gastro.2020.03.040>
23. Xu L, Lochhead P, Ko Y, Claggett B, Leong RW, Ananthakrishnan AN. Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. *Aliment Pharmacol Ther.* 2017;46(9):780–9. <https://doi.org/10.1111/apt.14291>
24. Laursen MF, Sakanaka M, von Burg N, Morbe U, Andersen D, Moll JM, et al. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. *Nat Microbiol.* 2021;6(11):1367–82. <https://doi.org/10.1038/s41564-021-00970-4>
25. Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature.* 2015;519(7541):92–6. <https://doi.org/10.1038/nature14232>
26. He Z, Chen L, Catalan-Dibene J, Bongers G, Faith JJ, Suebsuwong C, et al. Food colorants metabolized by commensal bacteria promote colitis in mice with dysregulated expression of interleukin-23. *Cell Metab.* 2021;33(7):1358–71.e5. <https://doi.org/10.1016/j.cmet.2021.04.015>
27. Narula N, Wong ECL, Dehghan M, Mente A, Rangarajan S, Lanas F, et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. *BMJ.* 2021;374:n1554. <https://doi.org/10.1136/bmj.n1554>
28. Lo CH, Khandpur N, Rossato SL, Lochhead P, Lopes EW, Burke KE, et al. Ultra-processed foods and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. *Clin Gastroenterol Hepatol.* 2022;20(6):e1323–37. <https://doi.org/10.1016/j.cgh.2021.08.031>
29. Chassaing B, Compher C, Bonhomme B, Liu Q, Tian Y, Walters W, et al. Randomized controlled-feeding study of dietary emulsifier carboxymethylcellulose reveals detrimental impacts on the gut microbiota and metabolome. *Gastroenterology.* 2022;162(3):743–56. <https://doi.org/10.1053/j.gastro.2021.11.006>
30. Khalili H, Håkansson N, Chan SS, Chen Y, Lochhead P, Ludvigsson JF, et al. Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies. *Gut.* 2020;69(9):1637–44. <https://doi.org/10.1136/gutjnl-2019-319505>
31. Adolph TE, Meyer M, Schwarzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. *Nat Rev Gastroenterol Hepatol.* 2022. <https://doi.org/10.1038/s41575-022-00658-y>
32. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, et al. Predictors of response to infliximab in patients with Crohn's disease. *Gastroenterology.* 2002;123(3):707–13. <https://doi.org/10.1053/gast.2002.35390>
33. Torres J, Caprioli F, Katsanos KH, Lobaton T, Micic D, Zeroncio M, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. *J Crohns Colitis.* 2016;10(12):1385–94. <https://doi.org/10.1093/ecco-jcc/jjw116>
34. Russell RK, Farhadi R, Wilson M, Drummond H, Satsangi J, Wilson DC. Perinatal passive smoke exposure may be more important than childhood exposure in the risk of developing childhood IBD. *Gut.* 2005;54:1500–1; author reply 1501.
35. van der Sloot KWJ, Weersma RK, Alizadeh BZ, Dijkstra G. Identification of environmental risk factors associated with the development of inflammatory bowel disease. *J Crohns Colitis.* 2020;14(12):1662–71.
36. Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. *Inflamm Bowel Dis.* 2007;13(4):431–8. <https://doi.org/10.1002/ibd.20070>

37. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al. Epigenetic signatures of cigarette smoking. *Circ Cardiovasc Genet*. 2016;9:436–47.
38. Wiklund P, Karhunen V, Richmond RC, Parmar P, Rodriguez A, De Silva M, et al. DNA methylation links prenatal smoking exposure to later life health outcomes in offspring. *Clin Epigenet*. 2019;11(1):97. <https://doi.org/10.1186/s13148-019-0683-4>
39. Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. *Nat Commun*. 2016;7(1):13507. <https://doi.org/10.1038/ncomms13507>
40. McDermott E, Ryan EJ, Tosetto M, Gibson D, Burrage J, Keegan D, et al. DNA methylation profiling in inflammatory bowel disease provides new insights into disease pathogenesis. *J Crohns Colitis*. 2016;10(1):77–86. <https://doi.org/10.1093/ecco-jcc/jjv176>
41. Khalili H, Ananthakrishnan AN, Konijeti GG, Liao X, Higuchi LM, Fuchs CS, et al. Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. *BMJ*. 2013;347:f6633. <https://doi.org/10.1136/bmj.f6633>
42. Agrawal M, Sabino J, Frias-Gomes C, Hillenbrand CM, Soudant C, Axelrad JE, et al. Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses. *EclinicalMedicine*. 2021;36:100884. <https://doi.org/10.1016/j.eclinm.2021.100884>
43. Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. *Gastroenterology*. 2019;157(3):647–59.e4. <https://doi.org/10.1053/j.gastro.2019.04.016>
44. Axelrad JE, Cadwell KH, Colombel JF, Shah SC. Systematic review: gastrointestinal infection and incident inflammatory bowel disease. *Aliment Pharmacol Ther*. 2020;51(12):1222–32. <https://doi.org/10.1111/apt.15770>
45. Jess T, Simonsen J, Nielsen NM, Jorgensen KT, Bager P, Ethelberg S, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. *Gut*. 2011;60(3):318–24. <https://doi.org/10.1136/gut.2010.223396>
46. Lin KD, Chiu GF, Waljee AK, Owyang SY, El-Zaatari M, Bishu S, et al. Effects of anti-*Helicobacter pylori* therapy on incidence of autoimmune diseases, including inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2019;17(10):1991–9. <https://doi.org/10.1016/j.cgh.2018.12.014>
47. Agrawal M, Burisch J, Colombel JF, Shah S C. Viewpoint: inflammatory bowel diseases among immigrants from low- to high-incidence countries: opportunities and considerations. *J Crohns Colitis*. 2020;14(2):267–73. <https://doi.org/10.1093/ecco-jcc/jjz139>
48. Arnold IC, Hitzler I, Muller A. The immunomodulatory properties of *Helicobacter pylori* confer protection against allergic and chronic inflammatory disorders. *Front Cell Infect Microbiol*. 2012;2:10. <https://doi.org/10.3389/fcimb.2012.00010>
49. Bach JF. Revisiting the hygiene hypothesis in the context of autoimmunity. *Front Immunol*. 2020;11:615192. <https://doi.org/10.3389/fimmu.2020.615192>
50. Agrawal M, Poulsen G, Colombel JF, Allin KH, Jess T. Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study. *Gut*. 2022:2022-327724 (Online ahead of print). <https://doi.org/10.1136/gutjnl-2022-327724>
51. Canova C, Ludvigsson JF, Di Domenicantonio R, Zanier L, Barbiellini Amidei C, Zingone F. Perinatal and antibiotic exposures and the risk of developing childhood-onset inflammatory bowel disease: a nested case-control study based on a population-based birth cohort. *Int J Environ Res Publ Health*. 2020;17(7):2409. <https://doi.org/10.3390/ijerph17072409>
52. Faye AS, Allin KH, Iversen A, Agrawal M, Faith J, Colombel JF, et al. 400: antibiotics as a risk factor for older onset IBD: population-based cohort study. *Gastroenterology*. 2022;162(7):S-87. [https://doi.org/10.1016/s0016-5085\(22\)60221-x](https://doi.org/10.1016/s0016-5085(22)60221-x)
53. Nguyen LH, Örtqvist AK, Cao Y, Simon TG, Roelstraete B, Song M, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. *Lancet Gastroenterol Hepatol*. 2020;5(11):986–95.
54. Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. *Nat Microbiol*. 2018;3(11):1255–65. <https://doi.org/10.1038/s41564-018-0257-9>
55. Agrawal M, Allin KH, Iversen AT, Mehandru S, Colombel JF, Jess T. Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study. *Am J Gastroenterol*. 2022 (Online ahead of print). <https://doi.org/10.14309/ajg.000000000001933>
56. Andersson RE, Olaison G, Tysk C, Ekbohm A. Appendectomy and protection against ulcerative colitis. *N Engl J Med*. 2001;344(11):808–14. <https://doi.org/10.1056/nejm200103153441104>
57. Frisch M, Pedersen BV, Andersson RE. Appendicitis, mesenteric lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. *BMJ*. 2009;338(mar09 2):b716. <https://doi.org/10.1136/bmj.b716>
58. Nyboe Andersen N, Gørtz S, Frisch M, Jess T. Reduced risk of UC in families affected by appendicitis: a Danish national cohort study. *Gut*. 2017;66(8):1398–402. <https://doi.org/10.1136/gutjnl-2015-311131>
59. Welsh S, Sam Z, Seenan JP, Nicholson GA. The role of appendectomy in ulcerative colitis: systematic review and meta-analysis. *Inflamm Bowel Dis*. 2022 (Online ahead of print).
60. Marques AH, O'Connor TG, Roth C, Susser E, Bjorke-Monsen AL. The influence of maternal prenatal and early childhood nutrition and maternal prenatal stress on offspring immune system development and neurodevelopmental disorders. *Front Neurosci*. 2013;7:120. <https://doi.org/10.3389/fnins.2013.00120>
61. Miyoshi J, Miyoshi S, Delmont TO, Cham C, Lee ST, Sakatani A, et al. Early-life microbial restitution reduces colitis risk promoted by antibiotic-induced gut dysbiosis in interleukin 10(–/–) mice. *Gastroenterology*. 2021;161(3):940–52.e15. <https://doi.org/10.1053/j.gastro.2021.05.054>
62. Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD across the age spectrum: is it the same disease? *Nat Rev Gastroenterol Hepatol*. 2014;11(2):88–98. <https://doi.org/10.1038/nrgastro.2013.240>
63. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. *Lancet*. 2017;389(10080):1741–55. [https://doi.org/10.1016/s0140-6736\(16\)31711-1](https://doi.org/10.1016/s0140-6736(16)31711-1)
64. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet*. 2017;389(10080):1756–70. [https://doi.org/10.1016/s0140-6736\(16\)32126-2](https://doi.org/10.1016/s0140-6736(16)32126-2)
65. Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. *Nat Rev Gastroenterol Hepatol*. 2022 (Online ahead of print). <https://doi.org/10.1038/s41575-022-00634-6>
66. Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, et al. Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors. *Aliment Pharmacol Ther*. 2019;49(5):564–71. <https://doi.org/10.1111/apt.15107>
67. Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, et al. The cost of inflammatory bowel disease: an initiative from the Crohn's & colitis foundation. *Inflamm Bowel Dis*. 2020;26(1):1–10.
68. Holko P, Kawalec P, Sajak-Szczerba M, Avedano L, Mossakowska M. Indirect costs of inflammatory bowel diseases: a comparison of

- patient-reported outcomes across 12 European countries. *Inflamm Bowel Dis.* 2022 (Online ahead of print).
69. Kisling LA, Das JM. Prevention strategies. In: *StatPearls* [Internet]. Treasure Island; 2022.
 70. Frazzei G, van Vollenhoven RF, de Jong BA, Siegelaar SE, van Schaardenburg D. Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes. *Front Immunol.* 2022;13:899372. <https://doi.org/10.3389/fimmu.2022.899372>
 71. Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. *Aliment Pharmacol Ther.* 2020;51(9):831–42. <https://doi.org/10.1111/apt.15685>
 72. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the international Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. *Gastroenterology.* 2021;160(5):1570–83. <https://doi.org/10.1053/j.gastro.2020.12.031>
 73. Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, et al. Deep remission at 1 year prevents progression of early Crohn's disease. *Gastroenterology.* 2020;159:139–47. <https://doi.org/10.1053/j.gastro.2020.03.039>
 74. Cleveland NK, Bressler B, Siegel CA, Baidoo L, Cheifetz AS, Colombel JF, et al. A summary of the BRIDGe summit on damage-related progression of ulcerative colitis: establishing research priorities. *Gastroenterology.* 2022. <https://doi.org/10.1053/j.gastro.2022.08.013>
 75. Kochar B, Ufere NN, Ritchie CS, Lai JC. The 5Ms of geriatrics in gastroenterology: the path to creating age-friendly care for older adults with inflammatory bowel diseases and cirrhosis. *Clin Transl Gastroenterol.* 2022;13(1):e00445. <https://doi.org/10.14309/ctg.000000000000445>
 76. Schoepfer A, Santos J, Fournier N, Schibli S, Spalinger J, Vavricka S, et al. Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset Crohn's disease. *J Crohns Colitis.* 2019;13(10):1334–42. <https://doi.org/10.1093/ecco-jcc/jjz065>
 77. Nahon S, Lahmek P, Paupard T, Lesgourgues B, Chaussade S, Peyrin-Biroulet L, et al. Diagnostic delay is associated with a greater risk of early surgery in a French cohort of Crohn's disease patients. *Dig Dis Sci.* 2016;61(11):3278–84. <https://doi.org/10.1007/s10620-016-4189-z>
 78. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, et al. Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. *J Crohns Colitis.* 2015;9(8):601–6. <https://doi.org/10.1093/ecco-jcc/jjv067>
 79. Fiorino G, Bonovas S, Gilardi D, Di Sabatino A, Allocca M, Furfaro F, et al. Validation of the red flags index for early diagnosis of Crohn's disease: a prospective observational IG-IBD study among general practitioners. *J Crohns Colitis.* 2020;14(12):1777–9. <https://doi.org/10.1093/ecco-jcc/jjaa111>
 80. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. *Am J Gastroenterol.* 2015;110(4):564–71. <https://doi.org/10.1038/ajg.2015.50>
 81. Burisch J, Jess T, Egeberg A. Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark. *Clin Gastroenterol Hepatol.* 2019;17(13):2704–12.
 82. Torres J, Gomes C, Jensen C, Agrawal M, Morão F, Jess T, et al. Risk factors for developing inflammatory bowel disease within and across families with family history of IBD. *J Crohns Colitis.* 2022 (Online ahead of print).
 83. Torres J, Ungaro RC, Colombel JF. Is prevention the best way to modify inflammatory bowel disease? How close are we? *Gastroenterology.* 2022;162(5):1452–5. <https://doi.org/10.1053/j.gastro.2021.07.051>
 84. Turpin W, Lee S-H, Raygoza Garay JA, Madsen KL, Meddings JB, Bedrani L, et al. Increased intestinal permeability is associated with later development of Crohn's disease. *Gastroenterology.* 2020;159:2092–100.e5.
 85. Galipeau HJ, Caminero A, Turpin W, Bermudez-Brito M, Santiago A, Libertucci J, et al. Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. *Gastroenterology.* 2021;160(5):1532–45. <https://doi.org/10.1053/j.gastro.2020.12.004>
 86. Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 Years before diagnosis. *Gastroenterology.* 2020;159(1):96–104. <https://doi.org/10.1053/j.gastro.2020.03.007>
 87. Mortha A, Remark R, Del Valle DM, Chuang LS, Chai Z, Alves I, et al. Neutralizing anti-granulocyte macrophage-colony stimulating factor Autoantibodies recognize post-translational glycosylations on granulocyte macrophage-colony stimulating factor years before diagnosis and predict complicated Crohn's disease. *Gastroenterology.* 2022;163(3):659–70. <https://doi.org/10.1053/j.gastro.2022.05.029>
 88. Federici S, Kredon-Russo S, Valdes-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. *Cell.* 2022;185(16):2879–98.e24. <https://doi.org/10.1016/j.cell.2022.07.003>

How to cite this article: Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. *United European Gastroenterol J.* 2022;10(10):1113–20. <https://doi.org/10.1002/ueg2.12317>